PAA 2.50% 20.5¢ pharmaust limited

Ann: Final MND Patient in Cohort 4 Successfully Completes Dosing, page-23

  1. 382 Posts.
    lightbulb Created with Sketch. 66
    Again expectation met with disappointment.

    No urgency nothing to ignite shareholder value.

    Us common shareholders let down again, I guess a BP will be the one that benefits as trials progress.

 
watchlist Created with Sketch. Add PAA (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.